Early clinical data validate rare immune cell for Adicet’s off-the-shelf cancer therapy

Healthcare

lymphoma

Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data that bring some validation to the approach.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.